Compare CMPR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | VCEL |
|---|---|---|
| Founded | 1994 | 1989 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2005 | 1996 |
| Metric | CMPR | VCEL |
|---|---|---|
| Price | $73.35 | $35.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $86.50 | $57.50 |
| AVG Volume (30 Days) | 125.6K | ★ 395.2K |
| Earning Date | 04-29-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 2.26 | 0.32 |
| Revenue | ★ $3,403,079,000.00 | $276,259,000.00 |
| Revenue This Year | $10.43 | $18.02 |
| Revenue Next Year | $5.46 | $18.52 |
| P/E Ratio | ★ $32.18 | $117.72 |
| Revenue Growth | 3.38 | ★ 16.45 |
| 52 Week Low | $35.28 | $29.24 |
| 52 Week High | $82.43 | $52.06 |
| Indicator | CMPR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 43.12 |
| Support Level | $62.44 | $34.61 |
| Resistance Level | $76.14 | $38.48 |
| Average True Range (ATR) | 3.26 | 1.70 |
| MACD | -0.30 | 0.06 |
| Stochastic Oscillator | 41.62 | 38.29 |
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.